Your browser doesn't support javascript.
loading
Coronary Atherosclerosis, Cardiac Troponin, and Interleukin-6 in Patients With Chest Pain: The PROMISE Trial Results.
Ferencik, Maros; Mayrhofer, Thomas; Lu, Michael T; Bittner, Daniel O; Emami, Hamed; Puchner, Stefan B; Meyersohn, Nandini M; Ivanov, Alexander V; Adami, Elizabeth C; Voora, Deepak; Ginsburg, Geoffrey S; Januzzi, James L; Douglas, Pamela S; Hoffmann, Udo.
Afiliação
  • Ferencik M; Knight Cardiovascular Institute, Oregon Health and Science University, Portland, Oregon, USA; Cardiovascular Research Imaging Center, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. Electronic address: ferencik@ohsu.edu.
  • Mayrhofer T; Cardiovascular Research Imaging Center, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA; School of Business Studies, Stralsund University of Applied Sciences, Stralsund, Germany.
  • Lu MT; Cardiovascular Research Imaging Center, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Bittner DO; Cardiovascular Research Imaging Center, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA; Friedrich-Alexander University Erlangen-Nürnberg (FAU), Department of Cardiology, Erlangen, Germany.
  • Emami H; Cardiovascular Research Imaging Center, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Puchner SB; Cardiovascular Research Imaging Center, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA; Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria.
  • Meyersohn NM; Cardiovascular Research Imaging Center, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Ivanov AV; Cardiovascular Research Imaging Center, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Adami EC; Cardiovascular Research Imaging Center, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Voora D; Duke Center for Applied Genomics and Precision Medicine, Duke University School of Medicine, Durham, North Carolina, USA.
  • Ginsburg GS; All of Us Research Program, National Institutes of Health, Bethesda, Maryland, USA.
  • Januzzi JL; Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Douglas PS; Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.
  • Hoffmann U; Cardiovascular Research Imaging Center, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
JACC Cardiovasc Imaging ; 15(8): 1427-1438, 2022 08.
Article em En | MEDLINE | ID: mdl-35926901
ABSTRACT

BACKGROUND:

Increased inflammation and myocardial injury can be observed in the absence of myocardial infarction or obstructive coronary artery disease (CAD).

OBJECTIVES:

The authors determined whether biomarkers of inflammation and myocardial injury-interleukin (IL)-6 and high-sensitivity cardiac troponin (hs-cTn)-were associated with the presence and extent of CAD and were independent predictors of major adverse cardiovascular events (MACEs) in stable chest pain.

METHODS:

Using participants from the PROMISE trial, the authors measured hs-cTn I and IL-6 concentrations and analyzed computed tomography angiography (CTA) images in the core laboratory for CAD characteristics significant stenosis (≥70%), high-risk plaque (HRP), Coronary Artery Disease Reporting and Data System (CAD-RADS) categories, segment involvement score (SIS), and coronary artery calcium (CAC) score. The primary endpoint was a composite MACE (death, myocardial infarction, or unstable angina).

RESULTS:

The authors included 1,796 participants (age 60.2 ± 8.0 years; 47.5% men, median follow-up 25 months). In multivariable linear regression adjusted for atherosclerotic cardiovascular disease (ASCVD) risk, hs-cTn was associated with HRP, stenosis, CAD-RADS, and SIS. IL-6 was only associated with stenosis and CAD-RADS. hs-cTn above median (1.5 ng/L) was associated with MACEs in univariable analysis (HR 2.1 [95% CI 1.3-3.6]; P = 0.006), but not in multivariable analysis adjusted for ASCVD and CAD. IL-6 above median (1.8 ng/L) was associated with MACEs in multivariable analysis adjusted for ASCVD and HRP (HR 1.9 [95% CI 1.1-3.3]; P = 0.03), CAC (HR 1.9 [95% CI 1.0-3.4]; P = 0.04), and SIS (HR 1.8 [95% CI 1.0-3.2]; P = 0.04), but not for stenosis or CAD-RADS. In participants with nonobstructive CAD (stenosis 1%-69%), the presence of both hs-cTn and IL-6 above median was strongly associated with MACEs (HR 2.5-2.7 after adjustment for CAD characteristics).

CONCLUSIONS:

Concentrations of hs-cTn and IL-6 were associated with CAD characteristics and MACEs, indicating that myocardial injury and inflammation may each contribute to pathways in CAD pathophysiology. This association was most pronounced among participants with nonobstructive CAD representing an opportunity to tailor treatment in this at-risk group. (PROspective Multicenter Imaging Study for Evaluation of Chest Pain [PROMISE]; NCT01174550).
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença da Artéria Coronariana / Estenose Coronária / Placa Aterosclerótica / Infarto do Miocárdio Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença da Artéria Coronariana / Estenose Coronária / Placa Aterosclerótica / Infarto do Miocárdio Idioma: En Ano de publicação: 2022 Tipo de documento: Article